The FDA approval of Sarepta’s (SRPT) Duchenne muscular dystrophy (DMD) product, Exondys 51 (eteplirsen), surprised many analysts. Nonetheless, it doubled SRPT's price after the stock had already multiplied everal folds since the stock had been cremated. Good for those who dared to bet on SRPT in spite of the FDA’s independent advisory committee’s voting against the approval and the FDA hesitation to listen to the DMD patients’ parents’ and relatives’ demands for compassion. The FDA's and the committee’s lack of enthusiasm for the drug emanated from the fact that the . . .
This content is for paid subscribers.
Today’s Highlights September 22, 2016